Citations

Clear

3 citation(s) found for "Spallanzani, Andrea".

Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases
Kuchynka, Petr, Brucato, Antonio , Tschöpe, Carsten , Castelleti, Silvia, Cooper, Leslie T, Dweck, Marc R. , Heidecker, Bettina, Kuusisto, J, Lazaros, G, Merlo, M, Pantazis, Antonis, Rigopoulos, Angelos G. , Ristić, Arsen D, Imazio, M, Brucato, Antonio , Cameli, Matteo , Frustaci, Andrea , Klingel, Karin , Lazaros, George , Tschöpe, Carsten , Kuchynka, Petr , Cooper, Leslie T. , Dweck, Marc Richard , Heidecker, Bettina , Petersen, Steffen E. , Ristić, Arsen , Sedlák, František , Sheppard, Mary N. , Imazio, Massimo

Mayo Clinic

European Journal of Heart Failure | May 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag043 | PMID 42166484 Get It

Abstract Heart involvement in eosinophilia represents a rare entity with substantial cardiac morbidity and mortality. This disorder is often overlooked and diagnosed in its advanced stages. In a subgroup of patients with eosinophilic heart disease, peripheral blood eosinophilia may not be present, and the biopsy of the affected organ or tissue is essential to establish the correct diagnosis. In this clinical consensus statement, an expert consensus group reviews the epidemiology, aetiology, diagnosis, and management of eosinophilic heart disease. The aim of the document is to increase awareness about the cardiac involvement associated with eosinophilia in order to diagnose the disease in early phases and prevent deleterious heart damage and adverse outcomes of affected individuals. The spectrum of physiological and immunological derangements requires a multidisciplinary approach for optimal management of affected individuals.
Myocarditis Following COVID-19 Vaccine: Incidence, Presentation, Diagnosis, Pathophysiology, Therapy, and Outcomes Put Into Perspective. A Clinical Consensus Document Supported by the Heart Failure Association of the European Society of Cardiology (ESC) an
Heidecker, Bettina , Dagan, Noa , Balicer, Ran D. , Rosano, Giuseppe , Tschöpe, Carsten , Kelle, Sebastian , Poland, Gregory A., Martı́n, Pilar , Hare, Joshua M. , Pantazis, Antonis, Prasad, Sanjay, Lüscher, Thomas F. , Heidecker, Bettina , Tschöpe, Carsten , Eriksson, Urs , Coats, Andrew J.S. , Poland, Gregory A. , Frustaci, Andrea , Klingel, Karin , Cooper, Leslie T. , Imazio, Massimo

Mayo Clinic

European Journal of Heart Failure | September 6, 2022 | Volume: 24 | Issue: 11 | Pages: 2000-2018

10.1002/ejhf.2669 | PMID 36065751 Get It

Abstract Over 10 million doses of COVID-19 vaccines based on RNA technology, viral vectors, recombinant protein, and inactivated virus have been administered worldwide. Although generally very safe, post-vaccine myocarditis can result from adaptive humoral and cellular, cardiac-specific inflammation within days and weeks of vaccination. Rates of vaccine-associated myocarditis vary by age and sex with the highest rates in males between 12 and 39 years. The clinical course is generally mild with rare cases of left ventricular dysfunction, heart failure and arrhythmias. Mild cases are likely underdiagnosed as cardiac magnetic resonance imaging (CMR) is not commonly performed even in suspected cases and not at all in asymptomatic and mildly symptomatic patients. Hospitalization of symptomatic patients with electrocardiographic changes and increased plasma troponin levels is considered necessary in the acute phase to monitor for arrhythmias and potential decline in left ventricular function. In addition to evaluation for symptoms, electrocardiographic changes and elevated troponin levels, CMR is the best non-invasive diagnostic tool with endomyocardial biopsy being restricted to severe cases with heart failure and/or arrhythmias. The management beyond guideline-directed treatment of heart failure and arrhythmias includes non-specific measures to control pain. Anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs, and corticosteroids have been used in more severe cases, with only anecdotal evidence for their effectiveness. In all age groups studied, the overall risks of SARS-CoV-2 infection-related hospitalization and death are hugely greater than the risks from post-vaccine myocarditis. This consensus statement serves as a practical resource for physicians in their clinical practice, to understand, diagnose, and manage affected patients. Furthermore, it is intended to stimulate research in this area.
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Cascinu, Stefano , Sobrero, Alberto F. , Banzi, Maria , Seitz, Jean‐François, Barone, Carlo , Brenner, Baruch , Hofheinz, Ralf‐Dieter , Spallanzani, Andrea , García‐Carbonero, Rocio , Arriaga, Yull , Verma, Udit, Kappeler, Christian, Miriyala, Ashok, Kalmus, J., Falcone, Alfredo , Zaniboni, Alberto , Falcone, Alfredo , Cutsem, Eric Van , Martinelli, Erika , Ychou, Marc , Peeters, Marc , Maiello, Evaristo , André, Thierry , Grothey, Axel

Mayo Clinic

The Oncologist | September 6, 2018 | Volume: 24 | Issue: 2 | Pages: 185-192

10.1634/theoncologist.2018-0072 | PMID 30190299 Get It

Abstract Background In the phase III CORRECT trial, regorafenib significantly improved survival in treatment-refractory metastatic colorectal cancer (mCRC). The CONSIGN study was designed to further characterize regorafenib safety and allow patients access to regorafenib before market authorization. Methods This prospective, single-arm study enrolled patients in 25 countries at 186 sites. Patients with treatment-refractory mCRC and an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1 received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. The primary endpoint was safety. Progression-free survival (PFS) per investigator assessment was the only efficacy evaluation. Results In total, 2,872 patients were assigned to treatment and 2,864 were treated. Median age was 62 years, ECOG PS 0/1 was 47%/53%, and 74% had received at least three prior regimens for metastatic disease. Median treatment duration was three cycles. Treatment-emergent adverse events (TEAEs) led to dose reduction in 46% of patients. Regorafenib-related TEAEs led to treatment discontinuation in 9%. Grade 5 regorafenib-related TEAEs occurred in <1%. The most common grade ≥3 regorafenib-related TEAEs were hypertension (15%), hand–foot skin reaction (14%), fatigue (13%), diarrhea (5%), and hypophosphatemia (5%). Treatment-emergent grade 3–4 laboratory toxicities included alanine aminotransferase (6%), aspartate aminotransferase (7%), and bilirubin (13%). Ongoing monitoring identified one nonfatal case of regorafenib-related severe drug-induced liver injury per DILI Working Group criteria. Median PFS (95% confidence interval [CI]) was 2.7 months (2.6–2.7). Conclusion In CONSIGN, the frequency and severity of TEAEs were consistent with the known safety profile of regorafenib. PFS was similar to reports of phase III trials. ClinicalTrials.gov: NCT01538680. Implications for Practice Patients with metastatic colorectal cancer (mCRC) who fail treatment with standard therapies, including chemotherapy and monoclonal antibodies targeting vascular endothelial growth factor or epidermal growth factor receptor, have few treatment options. The multikinase inhibitor regorafenib was shown to improve survival in patients with treatment-refractory mCRC in the phase III CORRECT (N = 760) and CONCUR (N = 204) trials. However, safety data on regorafenib for mCRC in a larger number of patients were not available. The CONSIGN trial, carried out prospectively in more than 2,800 patients across 25 countries, confirmed the safety profile of regorafenib from the phase III trials and reinforced the importance of using treatment modifications to manage adverse events.